EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study

Hongbin Yu, Tian Chen, Jiawei Li, Xin Zhang iD, Yu Wu iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Hongbin Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Ritonavir, Hematologic Neoplasms, COVID-19 Drug Treatment, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This research was supported by National Natural Science Foundation (No. 82370171) and Natural Science Foundation of Sichuan Province (No. 2025ZNSFSC0989)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with haematological malignancies (HMs) are highly vulnerable to COVID‐19 due to their immunocompromised status, which leads to prolonged viral clearance and severe outcomes. Nirmatrelvir/ritonavir has shown efficacy in reducing severity and mortality in high‐risk COVID‐19 outpatients, but its effectiveness in hospitalized HM patients remains unclear. We conducted a retrospective study to assess the effectiveness of nirmatrelvir/ritonavir on mortality and viral clearance in hospitalized HM patients with mild‐to‐moderate COVID‐19 during China's first COVID‐19 surge. Mortality rate and viral clearance time were the primary end‐points. Cox proportional hazards models were used to detect factors associated with mortality and viral clearance. A total of 116 HM patients, with a median age of 47.2 years, hospitalized for a minimum of 5 days with mild‐to‐moderate COVID‐19, were included in this study. There was no difference in the 90‐day mortality rate between HM patients treated with nirmatrelvir/ritonavir within 5 days and those not treated (4.9% vs. 5.3%, p = 1.000). Nirmatrelvir/ritonavir use within 5 days reduced the time to viral clearance (hazard ratio [HR] = 1.59, 95% confidence interval [CI] 1.04–2.42). Nirmatrelvir/ritonavir use within 5 days in hospitalized HM patients with mild‐to‐moderate COVID‐19 does not reduce mortality but accelerates viral clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirHematologic NeoplasmsCOVID-19 Drug TreatmentSARS-CoV-2HumansMiddle AgedMaleRetrospective StudiesFemaleCOVID-19AdultHospitalizationAgedChinaTreatment Outcome

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2haematological malignancieshospitalizednirmatrelvir

Substanzen

Ritonavir

Autor:innen und Institutionen

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Xin Zhang, Yu Wu

Förderung

  • This research was supported by National Natural Science Foundation (No. 82370171) and Natural Science Foundation of Sichuan Province (No. 2025ZNSFSC0989).

Zitieren

APA

Yu, H., Chen, T., Li, J., Zhang, X., & Wu, Y. (2025). Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study. British Journal of Haematology. https://doi.org/10.1111/bjh.20039

Vancouver

Yu H, Chen T, Li J, Zhang X, Wu Y. Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study. British Journal of Haematology. 2025. doi:10.1111/bjh.20039

BibTeX
@article{Yu2025,
  author = {Yu, Hongbin and Chen, Tian and Li, Jiawei and Zhang, Xin and Wu, Yu},
  title = {Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild‐to‐moderate COVID ‐19: A retrospective study},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20039}
}
Kostenlos starten →